1 HERCEPTIN SC (trastuzumab injection) Product Monograph. Hoffmann-La Roche Limited. September 11, 2018. 2 Slamon D et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. N Engl J Med 2011 ...

Results of the multicenter, crossover PrefHER trial, which randomized 240 women undergoing neoadjuvant or adjuvant treatment for HER-positive breast cancer to 4 cycles each of IV trastuzumab or SC ...

The FDA has approved Phesgo™ (pertuzumab, trastuzumab, hyaluronidase-zzxf; Genentech), in combination with chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer.

Results. Twenty-two patients were enrolled. The mean total patient time in the treatment chair was 61.8 minutes shorter with SC versus IV HP (22.5 vs 84.3 minutes, P<0.0001).The mean total patient ...

Background: The subcutaneous presentation of trastuzumab has been recently incorporated into the treatment regimen of HER2-positive breast cancer (BC). Its use has been associated with cost savings ...

One-year follow-up of health-related quality of life in the Swedish PREDIX HER 2 trial, evaluating docetaxel, trastuzumab sc, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2 ...

Trastuzumab deruxtecan led to significantly longer overall survival than ramucirumab plus paclitaxel among patients ... Meredith Venerus, M.Sc., for assistance with the patient-reported ...

SC formulation takes two to five minutes to administer, rather than up to 90 minutes with the standard intravenous (IV) formulation MISSISSAUGA, ON, Sept. 13, 2018 /CNW/ - Hoffmann-La Roche ...

1 HERCEPTIN SC (trastuzumab injection) Product Monograph. Hoffmann-La Roche Limited. September 11, 2018. 2 Slamon D et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. N Engl J Med 2011 ...

Herceptin (Trastuzumab) Subcutaneous (SC) Formulation Approved In Canada For Treatment Of Her2-Positive Breast Cancer. By Reuters. September 13, 2018 12:16 PM UTC Updated ago Sept 13 ...